Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab versus alendronate in postmenopausal osteoporosis
NL-OMON43694Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Nov 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing Romosozumab followed by alendronate with Alendronate (2 arms). Started Nov 2012; status: active, not recruiting.
02
Drugs
romosozumabalendronate
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NL-OMON43694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43694.